Ascletis Joins Sagimet's US$80 Million in Crossover Financing with Premium Investors
Ascletis Joins Sagimet's US$80 Million in Crossover Financing with Premium Investors News provided by Share this article Share this article HANGZHOU, China and SHAOXING, China, Feb. 11, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today that Ascletis, through its wholly-owned subsidiary, participates in Sagimet Biosciences Inc.'s US$80 million in crossover financing, led by an undisclosed public equity healthcare investment fund with participation from other existing investors (Kleiner Perkins, New Enterprise Associates (NEA) and Rock Springs), along with new investors (...
Source: prnewswire.com